where do glp 1 drugs come from Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans Focus on Glucagon-like Peptide-1 Target:
Description
An oral option for obesity could expand the addressable population
However, further studies have revealed that -cells in the pancreatic islets, and neurons in the nucleus of the solitary tract are also able to produce GLP-1
The ACC recommends GLP-1R agonists for cardiovascular risk reduction in patients with T2DM and established ASCVD [114]
Norway 7.3.8.1
